Vaccines and fingolimod
A study of 136 people with MS found that those on fingolimod (Gilenya) were less likely to see the benefits of vaccinations against flu or tetanus, though around two in five people on the drug were protected.
MS Research Australia
Vaccination and immunisation - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - March 2, 2015 Category: Neurology Source Type: news
Oral Drug May Be Best in MS Patients Failing Initial Tx (CME/CE)
(MedPage Today) -- Fingolimod outshone other injectable drugs following MS disease activity. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 9, 2015 Category: American Health Source Type: news
MS Drug May Trigger Lymphopenia in Slim Women (CME/CE)
(MedPage Today) -- Fingolimod also increases risk in patients with low lymphocyte count. (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - December 26, 2014 Category: Neurology Source Type: news
Fingolimod (Gilenya) and lymphopenia risk
German and Swedish studies suggest that underweight women and people with a low lymphocyte count when they start treatment with fingolimod (Gilenya) have a higher risk of lymphopenia (a deficiency in white blood cells) and will need careful monitoring.
MedPage Today
Fingolimod (Gilenya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - December 26, 2014 Category: Neurology Source Type: news
Side effects of Gilenya and Tysabri
Review article includes varicella-zoster infections associated with fingolimod (Gilenya) and antiNMDA antibodies resulting from stopping treatment with natalizumab (Tysabri) .
MedPage Today
Fingolimod (Gilenya) - A to Z of MS
Natalizumab (Tysabri) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - December 18, 2014 Category: Neurology Source Type: news
Fingolimod Trial in Progressive MS Misses EndpointFingolimod Trial in Progressive MS Misses Endpoint
Novartis reports that topline results of the INFORMS trial show no benefit over placebo on disability measures for oral fingolimod treatment. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 1, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Novartis' Gilenya fails in study for a type of MS
ZURICH (Reuters) - Novartis AG said on Monday its drug Gilenya failed to meet its main goal in a late-stage study as a treatment for primary progressive multiple sclerosis (PPMS). (Source: Reuters: Health)
Source: Reuters: Health - December 1, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Fingolimod for PPMS trial
The INFORMS trial has found that fingolimod (Gilenya) was no better than placebo at treating people with primary progressive MS.
Novartis press release
Reuters
Primary progressive MS: an introduction (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - December 1, 2014 Category: Neurology Source Type: news
Fingolimod (Gilenya) not effective in primary progressive MS
Fingolimod (Gilenya) was no better than placebo at reducing measures of progression in people with primary progressive MS according to information announced today. (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - December 1, 2014 Category: Neurology Source Type: news
MS Focus: Gilenya Ups Zoster Risk
(MedPage Today) -- Risk with fingolimod doubled compared with placebo but still low. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - November 25, 2014 Category: Geriatrics Source Type: news
Fingolimod (Gilenya) eligibility extended in Scotland
The Scottish Medicines Consortium (SMC), which issues guidance on whether treatments should be funded by NHS Scotland, has announced that fingolimod can now also be prescribed for people with rapidly evolving severe relapsing remitting MS (RES RRMS). (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - October 13, 2014 Category: Neurology Source Type: news
Fingolimod in new therapeutic indication: Added benefit not proven, study finds
There are no data for patients with highly active RRMS who had received other pretreatment than interferon beta, or these data show no relevant differences. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 10, 2014 Category: Science Source Type: news
Fingolimod in new therapeutic indication: Added benefit not proven
(Institute for Quality and Efficiency in Health Care) There are no data for patients with highly active RRMS who had received other pretreatment than interferon beta, or these data show no relevant differences. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 10, 2014 Category: Global & Universal Source Type: news
PML in MS Patients Making Natalizumab-to-Fingolimod SwitchPML in MS Patients Making Natalizumab-to-Fingolimod Switch
A new report describes several cases of PML seen in patients with MS receiving fingolimod, all but 1 of which were treated previously with natalizumab. Authors say this patient had neuromyelitis optica, not MS, with atypical features. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 25, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
ACTRIMS/ECTRIMS Summary
A review of some of the research from the recent ACTRIMS/ECTRIMSconference, including daclizumab, generic glatiramer acetate, a fingolimod similar, body temperature, cholesterol, comorbidities, stem cells, cognition, genetics, vitamin D and diet.
National MS Society (USA)
Latest MS research updates (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - September 16, 2014 Category: Neurology Source Type: news
